Pfizer announced today the successful conclusion of their mRNA-based BNT162b2 vaccine for SARS-CoV-2 produced in partnership with BioNTech. This news comes shortly after...
Pfizer/BioNTech COVID-19 Vaccine Concludes Final Phase Testing
phase3
Interview with COVID-19 Vaccine Volunteer Skyler Mener
Recently I caught up with one volunteer who recently received an experimental vaccine from Pfizer. 21-year-old Skyler Mener is a Junior at Kutztown University of Pennsylvania majoring in Social Work. In late August...
Mass COVID-19 Public Vaccination Planned in Russia in October
According to the Russian health minister Mikhail Murashko, the program will first vaccinate doctors and teachers provided their first vaccine receives regulatory approval this month.
Final Phase of Moderna COVID-19 Vaccine Recieves Additional Funding
The agreement will expand funding by up to $472 million in part to support the Phase 3 study of mRNA-1273, the company's COVID-19 vaccine. This funding expands on Moderna's previous agreement with BARDA for $483 million.
India Claims COVID-19 Vaccine Available by August
We’re now learning Bharat Biotech announced an aggressive deadline of August 15, 2020 for COVID-19 availability. This is by far the most aggressive availability we’ve...
First Human Receives Imperial College COVID-19 Vaccine
A volunteer, who asked to remain anonymous, was verified as healthy and became the first to receive Imperial College London's unreleased vaccine for COVID-19. This is the first COVID-19 vaccine to use Dr. Robert Shattock's RNA-amplifying technique for inducing immunity against the virus.
Imperial College Begins First Phase of Human Trials for COVID-19 Vaccine
According to a press release today and keeping to the timeline set last week, Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London.
Moderna: Phase III COVID-19 Vaccine Testing in July
Moderna today announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against COVID-19.